Nevada-based Neurotrope (formerly BlueFlash Communications) has completed a reverse merger in which Neurotrope BioScience, based in Delaware, became a wholly owned subsidiary of the company.

Neurotrope is a biopharmaceutical and diagnostics company principally focused on developing two product platforms, a diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's, both of which are in the clinical testing stage. 

The company, now headquartered in Plantation, Fla., will continue the business of Neurotrope as a wholly owned subsidiary. The company's new management team includes Neurotrope's chairman of the board, Dr. John Abeles; its chief executive officer, Dr. Jim New; its chief scientific officer, Dr. Daniel Alkon; and its chief financial officer, Robert Weinstein.